Analysts Offer Predictions for Korro Bio FY2025 Earnings

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for shares of Korro Bio in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the company will post earnings of ($8.76) per share for the year, up from their previous estimate of ($8.91). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share.

Several other equities analysts have also recently issued reports on the company. Oppenheimer reduced their price objective on Korro Bio from $155.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday. Chardan Capital reissued a "buy" rating and set a $25.00 target price on shares of Korro Bio in a report on Tuesday. HC Wainwright decreased their price target on shares of Korro Bio from $115.00 to $100.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, Royal Bank of Canada lowered their price objective on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a research report on Wednesday, March 19th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $104.63.

Korro Bio Stock Down 9.3%

Shares of KRRO traded down $1.44 during midday trading on Monday, hitting $14.11. The company had a trading volume of 107,465 shares, compared to its average volume of 98,182. The stock has a market cap of $132.51 million, a price-to-earnings ratio of -1.49 and a beta of 2.66. The company's 50 day moving average price is $17.53 and its 200 day moving average price is $33.59. Korro Bio has a 52 week low of $11.13 and a 52 week high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($2.49) EPS for the quarter, beating analysts' consensus estimates of ($2.60) by $0.11. The business had revenue of $2.55 million during the quarter, compared to analysts' expectations of $0.13 million.

Institutional Investors Weigh In On Korro Bio

Hedge funds have recently modified their holdings of the business. AlphaQuest LLC raised its holdings in Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock valued at $83,000 after acquiring an additional 412 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Korro Bio by 3.0% during the 4th quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company's stock worth $563,000 after purchasing an additional 435 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Korro Bio by 9.0% in the fourth quarter. Bank of America Corp DE now owns 7,037 shares of the company's stock valued at $268,000 after purchasing an additional 581 shares in the last quarter. Rhumbline Advisers lifted its position in Korro Bio by 7.8% in the fourth quarter. Rhumbline Advisers now owns 9,602 shares of the company's stock worth $366,000 after purchasing an additional 691 shares during the period. Finally, Blair William & Co. IL increased its holdings in Korro Bio by 5.7% in the 4th quarter. Blair William & Co. IL now owns 12,895 shares of the company's stock valued at $491,000 after buying an additional 695 shares during the period. 13.18% of the stock is owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).